PharmaShots' Key Highlights of First Quarter 2023
PharmaShots
APRIL 3, 2023
of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.
40 
Let's personalize your content